Market Place
Sourcing Support
Merck & Ridgeback Start Ph 3 Study of LAGEVRIO™ for COVID-19
05 Dec 2024 //
BUSINESSWIRE
Wedgewood Launches Molnupiravir for FIP Treatment
18 Sep 2024 //
BUSINESSWIRE
With $640M in sales of Lagevrio, Merck bumps up revenue forecast
26 Oct 2023 //
FIERCE PHARMA
Merck`s Lagevrio to be sold commercially in November, HHS says
05 Oct 2023 //
FIERCE PHARMA
Merck`s Lagevrio may have triggered new COVID variants: study
26 Sep 2023 //
FIERCE PHARMA
Pfizer, Merck trim prices in China for Paxlovid, molnupiravir
04 Apr 2023 //
REUTERS
Merck asks EMA to reevaluate rejected Covid-19 antiviral
14 Mar 2023 //
ENDPTS
EU regulator recommends against approval for Merck`s COVID pill for adults
25 Feb 2023 //
REUTERS
Merck and Ridgeback Provide Update on EU MAA for LAGEVRIO
24 Feb 2023 //
BUSINESSWIRE
Merck falls short in PhIII Covid-19 prophylaxis trial, joining Pfizer
22 Feb 2023 //
ENDPTS
Merck Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating LAGEVRIO
21 Feb 2023 //
BUSINESSWIRE
China Approves Merck’s Covid Pill Amid Shortage of Drugs
31 Dec 2022 //
CAIXINGLOBAL
COVID-19 antiviral treatment shown to speed up recovery in trial
23 Dec 2022 //
PHARMAFILE
Ascletis reports positive data from Phase I Covid-19 prodrug trial
13 Dec 2022 //
CLINICALTRIALSARENA
Ascletis Announces Positive PhI Clinical Results of Oral RdRp Inhibitor ASC10
12 Dec 2022 //
PRNEWSWIRE
Merck & Ridgeback Provide Update on Clinical & Non-Clinical Studies of LAGEVRIO
06 Oct 2022 //
BUSINESSWIRE
Merck, Sinopharm agree on deal for China rights to Lagevrio
29 Sep 2022 //
FIERCEPHARMA
Dr. B Raises $8 Million for New Telehealth Service
16 Aug 2022 //
BUSINESSWIRE
Variant type and patient sex affect molnupiravir efficacy, study finds
01 Aug 2022 //
SCIENCEDAILY
FDA says it won`t allow state-licensed pharmacists to prescribe Merck`s Lagevrio
09 Jul 2022 //
ENDPTS
Merck and Ridgeback Announce New Data For LAGEVRIO From PIII MOVe-OUT Study
07 Jun 2022 //
BUSINESSWIRE
ICER`s latest cost analysis favors Paxlovid over molnupiravir
11 May 2022 //
FIERCEPHARMA
Merck raises 2022 forecast as COVID pill, cancer drug fuels profit beat
29 Apr 2022 //
REUTERS
Merck sold $3.2B worth Molnupiravir, driving first-quarter revenue growth
29 Apr 2022 //
CNBC
Pfizer’s Covid Pill Get WHO Endorsement for High-Risk Patients
22 Apr 2022 //
BLOOMBERG
Pfizer`s Paxlovid to be on tap for thousands more in the U.K.
13 Apr 2022 //
FIERCEPHARMA
Pfizer`s Paxlovid to be on tap for thousands more in the U.K.
12 Apr 2022 //
FIERCEPHARMA
Merck, Ridgeback to Present Data Demonstrating That Treatment With LAGEVRIO
01 Apr 2022 //
BUSINESSWIRE
WHO OKs molnupiravir as treatment for Covid-19, after new data from India
04 Mar 2022 //
ENDPTS
Anti-Covid Drug MOLNUPIRAVIR
24 Feb 2022 //
PRESS RELEASE
Lessons learnt from the second wave: Tracking possibility of drug demand
22 Feb 2022 //
TRIBUNEINDIA
The Covid treatment pill and big pharma will ultimately decide who gets it
20 Feb 2022 //
THEGUARDIAN
Merck’s Anti-Covid Pill Shows Better Effectiveness In Indian Study
19 Feb 2022 //
FORBES
FDA updates Merck`s Covid-19 pill EUA and reaffirms it as last resort
19 Feb 2022 //
ENDPTS
Kalbe and Amarox partner to market Covid-19 drug
18 Feb 2022 //
PHARMACEUTICAL-TECHNOLOGY
Merck struggles to win European approval for Covid antiviral pill
17 Feb 2022 //
FINANCIAL TIMES
Researchers identify a powerful combination of antivirals to treat COVID-19
14 Feb 2022 //
MEDICAL NET
Merck, Ridgeback Supplied 3.1M Courses of Molnupiravir to U.S. Government
08 Feb 2022 //
BUSINESSWIRE
Merck sees 2022 sales up nearly 20%, mostly on molnupiravir
04 Feb 2022 //
REUTERS
Merck and Ridgeback’s Molnupiravir Demonstrated Activity Against Omicron Variant
28 Jan 2022 //
BUSINESSWIRE
Laurus Labs inks pact with MPP to produce molnupiravir
21 Jan 2022 //
ECONOMIC TIMES
Biophore receives sub-license from MPP for molnupiravir for Covid treatment
21 Jan 2022 //
PHARMABIZ
Fermenta Bio licenses its technology for manufacturing molnupiravir to Aurigene
21 Jan 2022 //
PHARMABIZ
Natco, Biophore Pharma get nod to manufacture, market molnupiravir
20 Jan 2022 //
THEHINDUBUSINESSLINE
AHF Praises Merck for Generics – Urges Same from Vaccine Makers
20 Jan 2022 //
BUSINESSWIRE
Australian TGA grants approval to two oral medicines for Covid-19
20 Jan 2022 //
PHARMACEUTICAL-TECHNOLOGY
Beximco Pharma to manufacture molnupiravir for COVID-19
20 Jan 2022 //
PHARMATIMES
Natco Pharma signs pact with MPP to sell Molnupiravir capsules
20 Jan 2022 //
ECONOMIC TIMES
Merck, Ridgeback Announce Supply Agreement with UNICEF for Molnupiravir
18 Jan 2022 //
BUSINESSWIRE
Molnupiravir not taken in COVID treatment guidelines as harms outweigh benefits
13 Jan 2022 //
ECONOMIC TIMES
Molnupiravir not to be included in COVID clinical management protocol for now
12 Jan 2022 //
ECONOMICTIMES
Molnupiravir shouldn’t be given to people of reproductive age
12 Jan 2022 //
ECONOMICTIMES
Italy to receive 40,000 Merck antiviral drug doses next week - official
10 Jan 2022 //
REUTERS
Morocco authorizes Merck`s molnupiravir for COVID-19
07 Jan 2022 //
REUTERS
Mexico grants emergency use approval for Merck`s COVID-19 pill
07 Jan 2022 //
REUTERS
No safety concerns observed in molnupiravir phase-3 trial, shared data with DCGI
07 Jan 2022 //
ECONOMIC TIMES
Lupin launches Molnulup for COVID-19 treatment
07 Jan 2022 //
ECONOMIC TIMES
India to become hub for Covid-19 antiviral generic drugs: Fitch
07 Jan 2022 //
ECONOMIC TIMES
MSN to launch generic anti-COVID pill Molnupiravir under `Molulow` brand
07 Jan 2022 //
ECONOMICTIMES
Aurobindo Pharma launches COVID-19 drug Molnupiravir in India
06 Jan 2022 //
ECONOMIC TIMES
